Open AccessPegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin
Author(s) -
Tal Grenader,
Ora Rosengarten,
Rut Isacson,
Yevgeni Plotkin,
Alberto Gabizón
Publication year - 2012
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v3.i10.137
Subject(s) - carboplatin , medicine , response evaluation criteria in solid tumors , doxorubicin , ovarian cancer , chemotherapy , progressive disease , oncology , urology , nuclear medicine , gastroenterology , cancer , surgery , cisplatin
To assess the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) and carboplatin in patients with recurrent epithelial ovarian carcinoma (ROC), following disease progression on single agent PLD.